KNCV Tuberculosis Foundation
11
3
3
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB
Role: collaborator
Assessing Diagnostics At Point-of-care for Tuberculosis
Role: collaborator
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
Role: collaborator
Choice Architecture Based TB Preventive Therapy Prescribing
Role: collaborator
Triage Test for All Oral DR-TB Regimen (TRiAD Study)
Role: collaborator
DeMONSTRATE-TB Study in Ethiopia
Role: collaborator
Introduction of Dispersible 3HP Formulations for TB Preventive Treatment in Children: a Multi-country Evaluation
Role: collaborator
Community Initiated Preventive Therapy for TB
Role: collaborator
Qualitative Understanding of Community TB Services Pre and Post the CHIP-TB Trial
Role: collaborator
TB Reduction Through ART and TB Screening Project
Role: collaborator
Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya
Role: lead
All 11 trials loaded